A Ludwig Cancer Research study has discovered a novel means by which bacterial colonies in the small intestine support the generation of regulatory T cells—immune cells that suppress autoimmune reactions and inflammation.
A Ludwig Cancer Research study has identified a mechanism by which regulatory T cells, which suppress immune responses, adapt their metabolism to thrive in the harsh microenvironment of the tumor.
A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell—a family of promising immunotherapies for cancer—that can be switched on and off on demand.
Ludwig Cancer Research extends a warm welcome to Robert Schreiber, the newest member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research.
Ludwig Cancer Research is pleased to announce the appointment of Douglas Hanahan as a Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research.
Ludwig Cancer Research congratulates Ping-Chih Ho on his appointment as Associate Member at the Lausanne Branch of the Ludwig Institute for Cancer Research.
Ludwig Cancer Research congratulates Ping-Chih Ho on his selection by the European Molecular Biology Association (EMBO) as a member of its Young Investigator Programme.
Ludwig Cancer Research scientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents.
Ludwig Cancer Research congratulates Peter Ratcliffe on his receipt of the 2019 Nobel Prize for Physiology or Medicine. He was recognized by the Nobel Committee for his landmark discoveries on the mechanisms by which mammalian cells sense and respond to the availability of oxygen.
Ludwig Cancer Research welcomes Alexandra Johnson to the Board of Directors of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has uncovered a novel vulnerability in tumors that are driven by a common cancer gene known as MYC. Such cancers, it found, are highly dependent on the cell’s machinery for making fats and other lipids.
An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship between nutrition and cancer.
A Ludwig Cancer Research study led by Peter Ratcliffe and colleagues has discovered a previously overlooked oxygen sensor in animal cells that functions very much like one used by plants.
A Ludwig Cancer Research study has deciphered a complex molecular conversation between cancer and immune cells that is key to orchestrating the successful invasion of tumors by T cells that kill cancer cells.
To explain a person’s actions in the present, it sometimes helps to understand their past, including where they come from and how they were raised. This is also true of tumors. Delving into a tumor’s cellular lineage, a Ludwig Cancer Research study shows, can reveal weaknesses to target for customized therapies.
Ludwig Cancer Research released today the full breadth of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Ga., March 29 – April 3, 2019. Research conducted by more than 75 Ludwig scientists will be shared in plenary sessions, major symposiums, education sessions, poster sessions and more.
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed “atlas of cell states” for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.
Ludwig Cancer Research scientists report in the current issue of Nature Biotechnology a new and improved method to detect chemical modifications to DNA. These modifications—or “epigenetic” marks—help control gene expression and their aberrant distribution across the genome contributes to cancer progression and resistance to therapy.
A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies. Led by Ping-Chih Ho of the Lausanne Branch of the Ludwig Institute for Cancer Research and reported in the current issue of Nature Immunology, the study also identifies an existing diabetes drug that could be used to accomplish that feat.
Ludwig Cancer Research congratulates Johanna Joyce on her new role as Member of the Lausanne Branch of the Ludwig Institute for Cancer Research. Joyce will continue to lead her laboratory in exploring how non-cancerous cells within the tumor microenvironment support cancer progression, metastasis and drug resistance.
Ludwig Cancer Research is pleased to welcome Nancy E. Davidson to the Ludwig Institute Board of Directors. Nancy Davidson, a physician-scientist with extensive expertise in breast cancer research, is a leader in the cancer research community.
Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor (EGFR), a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme (GBM).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which cells enter a state of dormancy as tissues starved of oxygen become increasingly acidic. The study, led by Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research, has potentially significant implications for cancer therapy: Large swaths of solid tumors are often deprived of oxygen, and cells in such patches are thought to be a major source of drug resistance and disease relapses.
The American Society of Clinical Oncology (ASCO) will honor two Ludwig scientists at its 2018 Annual Meeting in Chicago, Ill., June 1-5, 2018.
Ludwig Cancer Research released today the full scope of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, Ill., April 14-18, 2018. Research conducted by more than 100 Ludwig scientists will be presented in symposiums, plenaries, town meetings, education sessions and poster sessions.
A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.
Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.
Ludwig Cancer Research extends its warmest congratulations to Don Cleveland, who has been a Member of the Ludwig Institute for Cancer Research since 1995 and today was awarded the prestigious Breakthrough Prize.
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.
Ludwig Cancer Research has released the scope of its participation at this year’s Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, November 16-19.
A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy.
Ludwig Cancer Research has released the scope of its participation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland, November 8-12.
A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response.
Ludwig researchers show how a method that physically expands tissues can improve early breast cancer diagnostics and extend the capabilities of ordinary pathology labs
Ludwig Cancer Research released today the full scope of Ludwig’s participation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.
The loss of the tumor suppressor gene PTEN has been linked to tumor growth and chemotherapy resistance in the almost invariably lethal brain cancer glioblastoma multiforme (GBM). Now, Ludwig researchers have shown that one way to override the growth-promoting effects of PTEN deletion is, surprisingly, to inhibit a separate tumor suppressor gene.
Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.
Ludwig researchers have shown that triple-negative breast cancer cells ramp up production of a key component of DNA in response to chemotherapy and that targeting this pathway could undermine their resistance to such therapies.
Ludwig researchers discover that circular DNA, once thought to be rare in tumor cells, is actually very common and seems to play a fundamental role in tumor evolution
Findings uncover an ancient mechanism that makes cancer cells invasive, explains melanoma’s resistance to therapy and opens the door to development of novel cancer therapies
It is with great pleasure that the Ludwig Institute for Cancer Research announces the appointment of Chi Van Dang as its Scientific Director.
The Ludwig Institute for Cancer Research extends a warm welcome to Barbara S. Jones, the newest member of our Board of Directors.
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body’s immune system from attacking tumors.
A Ludwig Cancer Research study published in the current issue of Scientific Reports describes a new method and risk model to assess how aggressive a bladder cancer is likely to be. “If confirmed in larger studies, our findings could help physicians get a better handle on how a patient’s bladder cancer is likely to progress and allow them to personalize treatment on the basis of that knowledge,” said Ralph Weichselbaum, director of the Ludwig Center at Chicago University, who led the study.
A Ludwig Cancer Research study has identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma (GBM) and shown how it can potentially be exploited for therapy.
A Ludwig Cancer Research study published online September 5th in Nature Immunology illuminates a key requirement for the function of regulatory T cells—immune cells that play a critical role in many biological processes, from suppressing inflammation and deadly autoimmunity to helping tumors evade immune attack. The findings also unravel the complex role these cells can play in the genesis and progression of certain gastrointestinal cancers.
A Ludwig Cancer Research study published in the current issue of Nature reports a novel technique to map specific chemical (or “epigenetic”) modifications made to the protein packaging of DNA using a small population of cells. Such epigenetic marks play a central role in the regulation of the genome’s expression.
Ludwig researchers working in collaboration with colleagues in Australia and the US have shown that fragments of tumor DNA circulating in the blood can be used to gauge the risk of colorectal cancer recurrence and the efficacy of chemotherapy following surgery. The finding, published today in the current issue of the journal Science Translational Medicine, is an important step toward the development of a non-invasive and more effective test for the detection, monitoring and treatment of cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right